BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time - PubMed (original) (raw)
Comparative Study
BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time
Yi Luo et al. Neurobiol Dis. 2003 Oct.
Abstract
The formation of Alzheimer's Abeta peptide is initiated when the amyloid precursor protein (APP) is cleaved by the enzyme beta-secretase (BACE1); inhibition of this cleavage has been proposed as a means of treating Alzheimer's disease. (AD) We have previously shown that young BACE1 knockout mice (BACE1 KO) do not generate Abeta but in other respects appear normal. Here we have extended this analysis to include both gene expression profiling and phenotypic assessment of older BACE1 KO animals to evaluate the impact of chronic Abeta deficiency. We did not detect global compensatory changes in neural gene expression in young BACE1 KO mice. In particular, expression of the beta-secretase homolog BACE2 was not upregulated. Furthermore, we found no structural alterations in any organ, including all central and peripheral neural tissues, of BACE1 KO mice up to 14 months of age. Aged BACE1 KO mice engineered to overexpress human APP (BACE1 KO/APPtg) did not develop amyloid plaques. These data provide evidence that neither beta-secretase nor Abeta plays a vital role in mouse physiology and that chronic beta-secretase inhibition could be a useful approach in treating AD.
Similar articles
- Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes.
Sun X, Wang Y, Qing H, Christensen MA, Liu Y, Zhou W, Tong Y, Xiao C, Huang Y, Zhang S, Liu X, Song W. Sun X, et al. FASEB J. 2005 May;19(7):739-49. doi: 10.1096/fj.04-3426com. FASEB J. 2005. PMID: 15857888 - Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis.
Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R. Zhao J, et al. J Neurosci. 2007 Apr 4;27(14):3639-49. doi: 10.1523/JNEUROSCI.4396-06.2007. J Neurosci. 2007. PMID: 17409228 Free PMC article. - Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.
Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, Zhang M, Yang Y, Cai F, Woodgett J, Song W. Ly PT, et al. J Clin Invest. 2013 Jan;123(1):224-35. doi: 10.1172/JCI64516. Epub 2012 Dec 3. J Clin Invest. 2013. PMID: 23202730 Free PMC article. - The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R. Vassar R. J Mol Neurosci. 2001 Oct;17(2):157-70. doi: 10.1385/JMN:17:2:157. J Mol Neurosci. 2001. PMID: 11816789 Review. - BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R. Vassar R. J Mol Neurosci. 2004;23(1-2):105-14. doi: 10.1385/JMN:23:1-2:105. J Mol Neurosci. 2004. PMID: 15126696 Review.
Cited by
- The duality of amyloid-β: its role in normal and Alzheimer's disease states.
Azargoonjahromi A. Azargoonjahromi A. Mol Brain. 2024 Jul 17;17(1):44. doi: 10.1186/s13041-024-01118-1. Mol Brain. 2024. PMID: 39020435 Free PMC article. Review. - Immunotherapies for Alzheimer's Disease-A Review.
Valiukas Z, Ephraim R, Tangalakis K, Davidson M, Apostolopoulos V, Feehan J. Valiukas Z, et al. Vaccines (Basel). 2022 Sep 14;10(9):1527. doi: 10.3390/vaccines10091527. Vaccines (Basel). 2022. PMID: 36146605 Free PMC article. Review. - Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
Morató X, Pytel V, Jofresa S, Ruiz A, Boada M. Morató X, et al. Int J Mol Sci. 2022 Aug 18;23(16):9305. doi: 10.3390/ijms23169305. Int J Mol Sci. 2022. PMID: 36012569 Free PMC article. Review. - Revisiting APP secretases: an overview on the holistic effects of retinoic acid receptor stimulation in APP processing.
Vitória JJM, Trigo D, da Cruz E Silva OAB. Vitória JJM, et al. Cell Mol Life Sci. 2022 Jan 28;79(2):101. doi: 10.1007/s00018-021-04090-4. Cell Mol Life Sci. 2022. PMID: 35089425 Free PMC article. Review. - AP-2 reduces amyloidogenesis by promoting BACE1 trafficking and degradation in neurons.
Bera S, Camblor-Perujo S, Calleja Barca E, Negrete-Hurtado A, Racho J, De Bruyckere E, Wittich C, Ellrich N, Martins S, Adjaye J, Kononenko NL. Bera S, et al. EMBO Rep. 2020 Jun 4;21(6):e47954. doi: 10.15252/embr.201947954. Epub 2020 Apr 23. EMBO Rep. 2020. PMID: 32323475 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials